Clinical trials: Healthy Subjects and Atopic Dermatitis Subjects
- Condition Healthy Subjects and Atopic Dermatitis Subjects
- Funder type Industry (pharma, biotech, devices)
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy subjects.
- Trial name
- NCT01423656
- Testing
- LEO 29102
- Where
- United Kingdom
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Dermatitis, Atopic
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)
This is a Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Health Subjects, and Subjects with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT04220411
- Testing
- AR100DP1
- Where
- Taiwan
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Arjil Pharmaceuticals LLC
Atopic Dermatitis
A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.
This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect of VC005 Tablets in healthy subjects
- Trial name
- NCT07533851
- Testing
- VC005 Tablets
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Asthma, Atopic Dermatitis
A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis
The purpose of this study is to evaluate the safety and tolerability of single ascending dose of CNTO 7160 administered intravenously (IV) in healthy participants and multiple dose administered IV in participants with asthma and…
- Conditions
- Asthma, Atopic Dermatitis, Healthy
- Trial name
- NCT02345928
- Testing
- Part 1: CNTO 7160, Part 2 (Asthma): CNTO 7160, Part 2 (Atopic Dermatitis): CNTO 7160
- Where
- 7 sites in Belgium, Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Atopic Dermatitis
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate…
- Trial name
- NCT05859724
- Testing
- NM26-2198
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Yellow Jersey Therapeutics AG
Atopic Dermatitis
Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis
Part 1: To investigate the safety and tolerability of intravenous (IV) or subcutaneous (SC) administration of a single dose of KHK4323 to Japanese or Caucasian healthy adult males in a double-blind, placebo-controlled study.
- Trial name
- NCT03846466
- Testing
- KHK4323 IV/S, KHK4323 SC/S, KHK4323 IV/M
- Where
- Japan
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Atopic Dermatitis
A First-in-Human Study of QY211 Gel in Adult Subjects
This is a phase Ia/Ib,Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of Single and Multiple Topical Doses of…
- Trial name
- NCT05843422
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis.
- Trial name
- NCT04271514
- Testing
- RPT193
- Where
- 14 sites in United States, Netherlands
- Volunteers
- 103 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064
This is a 6-part first-in-human study in up to approximately 184 participants. Parts 1 to 5 is in health volunteers and part 6 is in subjects with atopic dermatitis.
- Trial name
- NCT03918980
- Testing
- LOU064
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy, Atopic Dermatitis
A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis
This is a Phase 1 parallel-cohort study of crisaborole ointment 2% to evaluate the skin irritation potential in adult Japanese healthy subjects in Cohort 1, and to evaluate the safety, tolerability and PK in adult Japanese…
- Trial name
- NCT03260595
- Testing
- Crisaborole ointment 2%, Vehicle
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.
- Trial name
- NCT06438263
- Testing
- Rocatinlimab
- Where
- 3 sites in United States
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Amgen
Atopic Dermatitis
Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) doses of QLM3003 compared to placebo. Also, pharmacokinetics (PK) of qlm3003 will be evaluated.
- Trial name
- NCT05932888
- Testing
- QLM3003
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis
This is a phase 1, single-center, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of DS-2741a after subcutaneous injection in healthy Japanese male volunteers and Japanese participants with…
- Trial name
- NCT04211415
- Testing
- DS-2741a
- Where
- Japan
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream
The principle aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 39652 cream is administered cutaneously as single dose to subjects with atopic dermatitis and to healthy subjects.
- Trial name
- NCT01850849
- Testing
- LEO 39652 cream, cream vehicle
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Dermatitis, Atopic
Skin Irritation Study of GSK2894512 Cream
GSK2894512 is a novel anti-inflammatory agent that is currently under development for the topical treatment of atopic dermatitis and chronic plaque psoriasis.
- Trial name
- NCT02637206
- Testing
- GSK2894512 Cream, Vehicle Cream, Empty Patch
- Where
- Japan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
Dermatitis, Atopic
A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects
To assess the pharmacokinetics of 3 doses and the food effect of a single high dose of BBI-5000 capsules in healthy adult subjects.
- Trial name
- NCT02590289
- Testing
- BBI-5000
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Fresh Tracks Therapeutics, Inc.
Atopic Dermatitis
A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
A randomized, double-blind, placebo-controlled trial design was used to assess the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics, and immunogenicity of TQH2722 injection in healthy subjects.
- Trial name
- NCT05409326
- Testing
- TQH2722 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects
This trial will investigate the pharmacokinetics, immunogenicity, safety, and tolerability of LEO 138559 in healthy Japanese subjects.
- Trial name
- NCT05099133
- Testing
- LEO 138559
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC